Pellerito's Corner - May 2014

Author: Peter Pellerito, President & CEO
Facility: ImaCor Inc. Garden City, NY
Summary: As I look back over the last several years in critical care, I notice that there’s a growing appreciation for advanced hemodynamic management for high acuity patients worldwide. In the U.S. alone, ICU costs represent 1% of U.S. GDP or $100 billion. The number one cause of death remains multiple organ failure (MOF). We are dealing with the height of healthcare delivery and at its center is hemodynamic management.

“The End of the Beginning” in Managing Sepsis: The ProCESS trial

Author: Harold M. Hastings, PhD Co-Founder and CTO
Facility: ImaCor Inc. Garden City, NY
Summary: The ProCESS trial (ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, et al., A randomized trial of protocol-based care for early septic shock, N Engl J Med. 2014;370:1683-93) marks "perhaps the end of the beginning" (Winston Churchill, November 9, 1942) in the continuing revolution in managing sepsis. Over 1300 patients were randomly assigned “to one of three groups for 6 hours of resuscitation: protocol-based EGDT; protocol-based standard therapy that did not require the placement of a central venous catheter, administration of inotropes, or blood transfusions; or usual care.” Their key results: “in our multicenter, randomized trial, in which patients were identified early in the emergency department as having septic shock and received antibiotics and other nonresuscitation aspects of care promptly,” protocol-based resuscitation … did not improve outcomes. In addition, there was “no significant benefit of the mandated use of central venous catheterization and central hemodynamic monitoring in all patients.”

Pellerito's Corner - April 2014

Author: Peter Pellerito, President & CEO
Facility: ImaCor Inc. Garden City, NY
Summary: New Advanced Hemodynamic Management studies using hTEE published last month add to our catalogue of clinical evidence, two of them abstracts in preparation for the ISHLT 34th Annual Meeting and Scientific Sessions. The first abstract was written by the cardiothoracic team at Allegheny General Hospital (Pittsburgh, PA, USA), led by Subbarao Elapavaluru MD, and reports the benefits of using hTEE to manage high-acuity patients post-operatively. The second abstract, by Hitoshi Hirose MD, PhD et al., from Thomas Jefferson University Hospital (Philadelphia, PA, USA) points out the clinical and financial advantages of using hTEE to uncover the root cause of hemodynamic instability following open-heart surgery. The full studies will be made available following ISHLT.

Pellerito's Corner - March 2014

Author: Peter Pellerito, President & CEO
Facility: ImaCor Inc. Garden City, NY
Summary: 2014 started with as much enthusiasm for hTEE clinical and educational initiatives as we saw in 2013, and hTEE adoption continues to accelerate. It is fitting that in this education issue we share what we have learned from hTEE users over the past several months.

Basic assumptions and ways of thinking about managing hemodynamics are evolving. The hemodynamic management paradigm is shifting from a reactive to a proactive approach.

Software 2.3.0 with Imaging Enhancements

Author: Nic Heron, Director of Software Development
Facility: ImaCor Inc. Garden City, NY
Summary: ImaCor is pleased to announce a new release of its Zura EVO software to version 2.3.0. This release is replete with expanded imaging as well as the ability to easily capture patient information, as follows:

• Imaging depth extended to 18 cm;
• B-mode sector angle extended to 90 degrees (70 degrees still available as a user-configurable option);
• 6-second cineloop acquisition capability;
• Improved Help System accessibility;
• Bar code scanner option;
• Configurable required patient fields.

For more information please contact me at This email address is being protected from spambots. You need JavaScript enabled to view it..

South to the Future: Report from AATS/STS Tech Con, Orlando, FL

Author: Harold M. Hastings, PhD, Co-Founder and Chief Technology Officer
Facility: ImaCor Inc. Garden City, NY
Summary: I felt that I had gone “South to the Future” Sunday, January 28th at the STS/AATS Tech Con and STS meeting in Orlando, Florida. First was the Sunday morning session, “Adult Cardiac Track III: Next Generation Devices for Durable Mechanical Circulatory Support” featuring presentations on the future of mechanical cardiac support by leading academic physicians and device manufacturers; second was our Sunday evening symposium, featuring a "talk with the experts" on the present and future of hTEE in advanced cardiac surgery and mechanical circulatory support.

Pellerito's Corner - February 2014

Author: Peter Pellerito, President & CEO
Facility: ImaCor Inc. Garden City, NY
Summary: Partnership around the country continues to build. I want to first thank our customers and clinical leadership for their vision and training support. I am often asked by new and prospective users how to best implement hTEE, to ensure hTEE will be a good fit for their hospital. The answer is simple – it will fit well at their site because we customize the implementation to align with their clinical, unit, interdepartmental and institutional objectives.

Pellerito's Corner - January 2014

Author: Peter Pellerito, President & CEO
Facility: ImaCor Inc. Garden City, NY

Reporting Live from the SCCM

Author: Jeff Normand RDCS, Director of Marketing
Facility: ImaCor Inc. Garden City, NY
Summary: Greetings from San Francisco. This year’s SCCM conference had an estimated 6000 attendees and something for everyone: training workshops, educational symposia, posters, and dynamic presentations on topics covering the entire landscape of critical care medicine. At the ImaCor exhibit we spoke to hundreds of physicians about the challenges inside of the ICU. The overwhelming tone of the conversations was, "How are we going to manage more effectively and efficiently in the changing times ahead?" We appreciated the opportunity to learn more from these physicians and discuss their focus on improving patient critical care, especially in Hemodynamic Management.